On 19 February 2025, Shanghai Henlius Biotech announced that its HANBEITAI, biosimilar to Roche/Genentech’s Avastin® (bevacizumab) has received marketing approval from Bolivia’s Agencia Estatal de Medicamentos y Tecnologías en Salud (AGEMED) under the trade name Longiva™.
This is the drug’s first approval outside China (approved December 2021), making it the fourth self-developed product from Shanghai Henlius Biotech to be marketed overseas.
The first bevacizumab biosimilar was approved in the US in September 2017 and in Europe in January 2018.